Current Status of Immunotherapy for Lung Cancer and Future Perspectives

被引：19
作者：
Kim, Ho Cheol [1 ]
Choi, Chang-Min [1 ,2 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oncol, Seoul, South Korea
来源：
TUBERCULOSIS AND RESPIRATORY DISEASES | 2020年 / 83卷 / 01期
关键词：
Lung Neoplasms; Immunotherapy; Prognosis; Survival; IMMUNE CHECKPOINT INHIBITORS; ACQUIRED-RESISTANCE; ADVERSE EVENTS; BLOCKADE; PD-1; CHEMOTHERAPY; DOCETAXEL; NIVOLUMAB; LYMPHOCYTES; IMMUNOLOGY;
D O I：
10.4046/trd.2019.0039
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, new therapeutic strategies are needed to improve clinical outcomes. Immunotherapy through the use of immune checkpoint inhibitors has provided one of the most important breakthroughs in the management of solid tumors, including lung cancers, and has shown promising results in numerous clinical trials. This review will present the current status of immunotherapy for lung cancer and future perspectives on these treatments.
引用
收藏
页码：14 / 19
页数：6
相关论文
共 56 条
  • [1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
    Abdel-Wahab, Noha
    Shah, Mohsin
    Suarez-Almazor, Maria E.
    [J]. PLOS ONE, 2016, 11 (07):
  • [2] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
    Aberle, Denise R.
    Adams, Amanda M.
    Berg, Christine D.
    Black, William C.
    Clapp, Jonathan D.
    Fagerstrom, Richard M.
    Gareen, Ilana F.
    Gatsonis, Constantine
    Marcus, Pamela M.
    Sicks, JoRean D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) : 395 - 409
  • [3] CAR T-cell Therapy: A New Era in Cancer Immunotherapy
    Androulla, Miliotou N.
    Lefkothea, Papadopoulou C.
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2018, 19 (01) : 5 - 18
  • [4] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [5] Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
    Apetoh, L.
    Ladoire, S.
    Coukos, G.
    Ghiringhelli, F.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (09) : 1813 - 1823
  • [6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [7] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [8] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [9] Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
    Brahmer, Julie R.
    Pardoll, Drew M.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2013, 1 (02) : 85 - 91
  • [10] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
    Buchbinder, Elizabeth I.
    Desai, Anupam
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01): : 98 - 106
123456